Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 5:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hematopoietic Cell Transplantation (HCT) Clear all
Terminated Phase 1Phase 2 Interventional

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

NCT04849910
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions
VOR33, Mylotarg
Biological · Drug
Lead sponsor
Vor Biopharma
Industry
Eligibility
18 Years to 70 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
14
States / cities
La Jolla, California • Stanford, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Jun 26, 2026, 5:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

NCT02145403
View directory record Official record
Conditions
Hematologic Malignancies, Relapse, Graft-Versus-Host Disease
Interventions
Carfilzomib, Tacrolimus
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 2, 2022 · Synced Jun 26, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

FMT In High-Risk Acute GVHD After ALLO HCT

NCT04139577
View directory record Official record
Conditions
Acute Graft-Versus-Host Disease (Gvhd) Grade, Hematopoietic Cell Transplantation, Fecal Microbiota Transplant
Interventions
Fecal Microbiota Transplant
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Jun 26, 2026, 5:03 PM EDT
Recruiting Not applicable Interventional

Virtual Rehabilitation in HCT

NCT05943964
View directory record Official record
Conditions
Hematopoietic Cell Transplant
Interventions
Virtual exercise and rehabilitation program
Behavioral
Lead sponsor
Emory University
Other
Eligibility
8 Years to 23 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jun 26, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional Results available

Preservation of Ovarian Function After Hematopoietic Cell Transplant

NCT01343368
View directory record Official record
Conditions
Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease, Acute Myeloid Leukemia, Myeloproliferative Disorders
Interventions
Leuprolide, hematopoietic cell transplant, reduced intensity allogeneic HCT
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
50 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Jun 26, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

The Safety and Tolerability of Pirfenidone for BOS After HCT

NCT03315741
View directory record Official record
Conditions
Bronchiolitis Obliterans, Graft Vs Host Disease
Interventions
Pirfenidone 267 MG [Esbriet]
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2022 · Synced Jun 26, 2026, 5:03 PM EDT
Completed No phase listed Observational

Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies

NCT04710212
View directory record Official record
Conditions
Hematologic Malignancy, Leukemia, Acute, Neutropenia, Bloodstream Infection
Interventions
No intervention.
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
San Francisco, California • Nutley, New Jersey • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Jun 26, 2026, 5:03 PM EDT
Not yet recruiting Not applicable Interventional

Remotely Monitored, Mobile Health-supported, High Intensity Interval Training Before Hematopoietic Stem Cell Transplant

NCT06953648
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation, Cardiorespiratory Fitness
Interventions
High Intensity Interval Training
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Kansas City, Kansas • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Jun 26, 2026, 5:03 PM EDT
Active, not recruiting Not applicable Interventional

Mobile CARE-App to Promote Coping for Caregivers of Patients Receiving Stem Cell Transplant

NCT05709912
View directory record Official record
Conditions
Bone Marrow Transplant Complications, Hematologic Malignancy
Interventions
CARE Application, Usual Care
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Jun 26, 2026, 5:03 PM EDT
Terminated Phase 3 Interventional Results available

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

NCT00568633
View directory record Official record
Conditions
Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia (AML)
Interventions
Allogeneic HSCT, Anti-thymocyte globulin (ATG), Cyclosporine (CSP), Mycophenolate mofetil (MMF), Total lymphoid irradiation (TLI), Methylprednisolone sodium succinate, Best standard care
Procedure · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
5
States / cities
Hayward, California • Los Angeles, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Jun 26, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT

NCT01246206
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Tacrolimus and Thymoglobulin
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 17, 2018 · Synced Jun 26, 2026, 5:03 PM EDT
Completed No phase listed Observational

MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia

NCT01385787
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Not listed
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
Up to 21 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Jun 26, 2026, 5:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

NCT02780609
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor, Melphalan, Dexamethasone, Autologous Hematopoietic Cell Transplantation (HCT), Fosaprepitant
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Jun 26, 2026, 5:03 PM EDT
Recruiting Not applicable Interventional

Patient Navigation and the Planning Advance Care Together Website to Improve Goals of Care Conversations in Hematopoietic Cell Transplant Survivors, IMPACT-HCT Trial

NCT07052630
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
Internet-Based Intervention, Patient Navigation, Best Practice, Survey Administration
Other · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 26, 2026, 5:03 PM EDT
Terminated Phase 3 Interventional Results available

Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)

NCT00926575
View directory record Official record
Conditions
Acute Gastrointestinal Graft vs Host Disease
Interventions
oral beclomethasone 17,21-dipropionate, Placebo
Drug
Lead sponsor
Soligenix
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Buffalo, New York • Durham, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Jun 26, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

Safety Evaluation of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation

NCT03002519
View directory record Official record
Conditions
Incomplete HCT (Hematopoietic Cell Transplantation)
Interventions
PLX-R18
Biological
Lead sponsor
Pluristem Ltd.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
7
States / cities
Chicago, Illinois • Westwood, Kansas • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Jun 26, 2026, 5:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

ACT to Reduce Morbidity and Mortality in Hematopoietic Stem Cell Transplant (HCT) Patients

NCT04423939
View directory record Official record
Conditions
Hematopoietic Steam Cell Transplantation (HCT)
Interventions
Acceptance and Commitment Therapy (ACT)
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jun 26, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

NCT01877655
View directory record Official record
Conditions
Cytomegalovirus (CMV)-Positive Recipients, Allogeneic, Hematopoietic Cell Transplant (HCT)
Interventions
ASP0113, Placebo
Biological · Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
27
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Jun 26, 2026, 5:03 PM EDT
Recruiting Phase 2 Interventional

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

NCT05736419
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, Beta, Thalassemia
Interventions
Fludarabine, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Rabbit ATG, Dexamethasone, Bortezomib, Rituximab
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
2 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 26, 2026, 5:03 PM EDT
Recruiting Phase 2 Interventional

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

NCT06412497
View directory record Official record
Conditions
Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria
Interventions
Rituximab, Rabbit ATG, Cyclophosphamide, Fludarabine, Total Body Irradiation, Cell Infusion, Post-Transplant G-CSF, Tacrolimus, Mycophenolate Mofetil
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
0 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 26, 2026, 5:03 PM EDT
Completed No phase listed Observational

Developing Self-Management Interventions After HCT

NCT03710031
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplant (HSCT)
Interventions
PNS Tracking
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Jun 26, 2026, 5:03 PM EDT
Recruiting No phase listed Observational

Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation

NCT06649201
View directory record Official record
Conditions
Graft Vs Host Disease, Vulvovaginal Signs and Symptoms
Interventions
Vulvovaginal Symptom Questionnaire, Vaginal Microbiome Evaluation
Other · Diagnostic Test
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jun 26, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)

NCT02722941
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Panobinostat
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Jun 26, 2026, 5:03 PM EDT
Active, not recruiting No phase listed Observational

Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test

NCT04635384
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions
Not listed
Lead sponsor
CareDx
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
10
States / cities
Brisbane, California • Duarte, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jun 26, 2026, 5:03 PM EDT